eligibility_summary
Eligible: advanced solid tumors after failure/intolerance/no standard therapy, ECOG 0–1, survival ≥3 mo, adequate organs, tumor for TIL harvest (>1.5 cm3 resection or ≥6 biopsies) plus ≥1 measurable lesion after harvest. Exclude: other malignancy <5 yrs (except select cured), systemic/local or investigational therapy ≤4 wks, unresolved ≥G2 AEs (except alopecia or stable G2 hypothyroidism), prior allo-HSCT/solid organ transplant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial: Early-phase, single-arm study of LM103 autologous tumor-infiltrating lymphocytes (TILs) for advanced solid tumors. Interventions and types: LM103 (biological cell therapy, ≥5×10^9 autologous ex vivo–expanded T cells, i.v.), lymphodepletion with cyclophosphamide (alkylating chemotherapeutic) and fludarabine (purine analog antimetabolite), interleukin‑2 (cytokine therapy). Mechanisms of action: TILs recognize patient-specific tumor antigens via TCRs and mediate cytotoxic killing, IL‑2 promotes T‑cell proliferation/activation via IL‑2R/JAK‑STAT, cyclophosphamide/fludarabine deplete endogenous lymphocytes (including Tregs) to reduce immunosuppression and improve TIL engraftment. Cells/pathways targeted: tumor cells, adaptive anti‑tumor T‑cell immunity, TCR‑mediated cytotoxicity, IL‑2 signaling, and depletion of immunosuppressive lymphocyte populations.